Effects of short‐term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients | Zendy

Pedro Iglesias | Zendy; Juan J. Díez | Zendy; María José FernándezReyes | Zendy; Mc Auxiliadore Bajo | Zendy; Abelardo Aguilera | Zendy; Javier Valencia Méndez | Zendy; Rosa Codoceo | Zendy; Rafael Selgas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of short‐term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients

Author(s) -

Pedro Iglesias,

Juan J. Díez,

María José FernándezReyes,

Mc Auxiliadore Bajo,

Abelardo Aguilera,

Javier Valencia Méndez,

Rosa Codoceo,

Rafael Selgas

Publication year - 2002

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/17.2.260

Subject(s) - medicine , leptin , endocrinology , recombinant dna , dialysis , kidney disease , hemodialysis , hormone , insulin , human growth hormone , growth hormone , obesity , biology , biochemistry , gene

Hyperleptinaemia is a well-known biochemical feature found in uraemic patients. However, little is known about the hormonal regulation of leptin in chronic renal disease. Recent studies have shown that circulating leptin levels are modified by treatment with recombinant human growth hormone (rhGH), by recombinant insulin-like growth factor I (rhIGF I), or by a combination of rhIGF I plus rhGH in patients with chronic renal failure. We performed a prospective study to assess plasma leptin concentrations in a group of dialysis patients both before and during short-term rhGH therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research